JP2020500020A - 融合誘導性タンパク質minionに関連する組成物、方法、および治療上の使用 - Google Patents
融合誘導性タンパク質minionに関連する組成物、方法、および治療上の使用 Download PDFInfo
- Publication number
- JP2020500020A JP2020500020A JP2019524896A JP2019524896A JP2020500020A JP 2020500020 A JP2020500020 A JP 2020500020A JP 2019524896 A JP2019524896 A JP 2019524896A JP 2019524896 A JP2019524896 A JP 2019524896A JP 2020500020 A JP2020500020 A JP 2020500020A
- Authority
- JP
- Japan
- Prior art keywords
- seq
- cell
- minion
- polypeptide
- variant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/02—Preparation of hybrid cells by fusion of two or more cells, e.g. protoplast fusion
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/65—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression using markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0658—Skeletal muscle cells, e.g. myocytes, myotubes, myoblasts
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
- C12N5/12—Fused cells, e.g. hybridomas
- C12N5/14—Plant cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/80—Vaccine for a specifically defined cancer
- A61K2039/892—Reproductive system [uterus, ovaries, cervix, testes]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/60—Fusion polypeptide containing spectroscopic/fluorescent detection, e.g. green fluorescent protein [GFP]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/61—Fusion polypeptide containing an enzyme fusion for detection (lacZ, luciferase)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/10041—Use of virus, viral particle or viral elements as a vector
- C12N2740/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Cell Biology (AREA)
- Neurology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oncology (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Mycology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662421514P | 2016-11-14 | 2016-11-14 | |
| US62/421,514 | 2016-11-14 | ||
| PCT/IB2017/057060 WO2018087720A1 (en) | 2016-11-14 | 2017-11-10 | Compositions, methods, and therapeutic uses related to fusogenic protein minion |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020500020A true JP2020500020A (ja) | 2020-01-09 |
| JP2020500020A5 JP2020500020A5 (cg-RX-API-DMAC10.html) | 2020-12-24 |
Family
ID=60543617
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019524896A Ceased JP2020500020A (ja) | 2016-11-14 | 2017-11-10 | 融合誘導性タンパク質minionに関連する組成物、方法、および治療上の使用 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US11339209B2 (cg-RX-API-DMAC10.html) |
| EP (1) | EP3538546B1 (cg-RX-API-DMAC10.html) |
| JP (1) | JP2020500020A (cg-RX-API-DMAC10.html) |
| CN (1) | CN109996809A (cg-RX-API-DMAC10.html) |
| WO (1) | WO2018087720A1 (cg-RX-API-DMAC10.html) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2020508668A (ja) * | 2017-02-24 | 2020-03-26 | ザ ボード オブ リージェンツ オブ ザ ユニバーシティー オブ テキサス システム | ミオミキサーにより促進される筋細胞融合に関連する組成物および方法 |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3053142A1 (en) * | 2017-02-14 | 2018-08-23 | Children's Hospital Medical Center | Myomerger polypeptide, nucleic acid molecules, cells, and related methods |
| SG11202101581RA (en) * | 2017-08-09 | 2021-03-30 | Ohio State Innovation Foundation | Oncolytic virus carrying e-cadherin and uses thereof |
| WO2019241622A1 (en) * | 2018-06-15 | 2019-12-19 | Children's Hospital Medical Center | Polypeptides, nucleic acid molecules, compositions, and related methods |
| CN109679927B (zh) * | 2019-02-25 | 2021-04-09 | 中国农业科学院兰州兽医研究所 | 猪塞内加谷病毒、猪塞内加谷病毒灭活疫苗的制备方法、猪塞内加谷病毒灭活疫苗和应用 |
| US20220378841A1 (en) * | 2019-07-10 | 2022-12-01 | Children's Hospital Medical Center | Modified cells and related methods |
| US20230407334A1 (en) * | 2020-10-31 | 2023-12-21 | Children's Hospital Medical Center | Pseudotyped particles, modified cells, related compositions, and related methods |
| WO2023235206A1 (en) * | 2022-06-02 | 2023-12-07 | Rowan University | Room air monitoring device |
| CN116284224B (zh) * | 2023-05-12 | 2023-07-25 | 中国农业大学 | 一种结合Claudin 18.2的环肽及其应用 |
| CN118291538A (zh) * | 2024-04-01 | 2024-07-05 | 华南农业大学 | 宿主细胞的ocln基因在调控呼肠孤病毒复制中的应用 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014210448A1 (en) * | 2013-06-27 | 2014-12-31 | The Board Of Regents Of The University Of Texas System | Compositions and methods relating to myomaker-induced muscle cell fusion |
Family Cites Families (164)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1247080A (en) | 1983-03-08 | 1988-12-20 | Commonwealth Serum Laboratories Commission | Antigenically active amino acid sequences |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4789633A (en) | 1984-04-19 | 1988-12-06 | University Of Tennessee Research Corporation | Fused liposome and acid induced method for liposome fusion |
| US4925661A (en) | 1984-04-19 | 1990-05-15 | Leaf Huang | Target-specific cytotoxic liposomes |
| JPH0662517B2 (ja) | 1985-01-07 | 1994-08-17 | シンテツクス(ユー・エス・エイ)インコーポレイテツド | 置換アルキルートリ置換アンモニウム界面活性剤 |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US4983397A (en) | 1985-08-19 | 1991-01-08 | Board Of Regents, University Of Texas System | Pharmaceutical compositions consisting of acylated phospholipids |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| JPS63182029A (ja) | 1987-01-22 | 1988-07-27 | Agency Of Ind Science & Technol | リポソ−ム |
| JP3101690B2 (ja) | 1987-03-18 | 2000-10-23 | エス・ビィ・2・インコーポレイテッド | 変性抗体の、または変性抗体に関する改良 |
| US5049390A (en) | 1987-09-02 | 1991-09-17 | Allergy Immuno Technologies, Inc. | Liposome containing immunotherapy agents for treating IgE mediated allergies |
| US5677425A (en) | 1987-09-04 | 1997-10-14 | Celltech Therapeutics Limited | Recombinant antibody |
| US5476996A (en) | 1988-06-14 | 1995-12-19 | Lidak Pharmaceuticals | Human immune system in non-human animal |
| JPH0720857B2 (ja) | 1988-08-11 | 1995-03-08 | テルモ株式会社 | リポソームおよびその製法 |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| DK0737750T3 (da) | 1989-03-21 | 2003-09-01 | Vical Inc | Ekspression af exogene polynucleotidsekvenser i vertebrater |
| US5474772A (en) | 1989-08-02 | 1995-12-12 | Cobe Laboratories, Inc. | Method of treatment with medical agents |
| CA2025907A1 (en) | 1989-09-21 | 1991-03-22 | Franklin D. Collins | Method of transporting compositions across the blood brain barrier |
| US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| EP1690935A3 (en) | 1990-01-12 | 2008-07-30 | Abgenix, Inc. | Generation of xenogeneic antibodies |
| US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US6673986B1 (en) | 1990-01-12 | 2004-01-06 | Abgenix, Inc. | Generation of xenogeneic antibodies |
| US5279833A (en) | 1990-04-04 | 1994-01-18 | Yale University | Liposomal transfection of nucleic acids into animal cells |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| US6172197B1 (en) | 1991-07-10 | 2001-01-09 | Medical Research Council | Methods for producing members of specific binding pairs |
| US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| ES2246502T3 (es) | 1990-08-29 | 2006-02-16 | Genpharm International, Inc. | Animales no humanos transgenicos capaces de producir anticuerpos heterologos. |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US6300129B1 (en) | 1990-08-29 | 2001-10-09 | Genpharm International | Transgenic non-human animals for producing heterologous antibodies |
| US5874299A (en) | 1990-08-29 | 1999-02-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5789650A (en) | 1990-08-29 | 1998-08-04 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5877397A (en) | 1990-08-29 | 1999-03-02 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US6255458B1 (en) | 1990-08-29 | 2001-07-03 | Genpharm International | High affinity human antibodies and human antibodies against digoxin |
| US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
| WO1992007959A1 (en) | 1990-11-05 | 1992-05-14 | Biowhittaker Inc. | Homogeneous membrane lytic immunoassay method utilizing contact sensitive liposome formulations |
| US5554728A (en) | 1991-07-23 | 1996-09-10 | Nexstar Pharmaceuticals, Inc. | Lipid conjugates of therapeutic peptides and protease inhibitors |
| US5283185A (en) | 1991-08-28 | 1994-02-01 | University Of Tennessee Research Corporation | Method for delivering nucleic acids into cells |
| US6509032B1 (en) | 1991-08-28 | 2003-01-21 | Mcmaster University | Cationic amphiphiles |
| US5292524A (en) | 1991-09-06 | 1994-03-08 | California Institute Of Technology | Blood platelet loaded with diagnostic or therapeutic-containing liposome or reconstituted Sendai virus |
| PT1024191E (pt) | 1991-12-02 | 2008-12-22 | Medical Res Council | Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos |
| JPH07503132A (ja) | 1991-12-17 | 1995-04-06 | ジェンファーム インターナショナル,インコーポレイティド | 異種抗体を産生することができるトランスジェニック非ヒト動物 |
| US5858784A (en) | 1991-12-17 | 1999-01-12 | The Regents Of The University Of California | Expression of cloned genes in the lung by aerosol- and liposome-based delivery |
| US5714350A (en) | 1992-03-09 | 1998-02-03 | Protein Design Labs, Inc. | Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region |
| JPH07505283A (ja) | 1992-03-20 | 1995-06-15 | ベイラー・カレッジ・オブ・メディシン | Dnaトランスポーター系および使用方法 |
| AU682308C (en) | 1992-04-03 | 2006-08-17 | Regents Of The University Of California, The | Self-assembling polynucleotide delivery system |
| AU4116793A (en) | 1992-04-24 | 1993-11-29 | Board Of Regents, The University Of Texas System | Recombinant production of immunoglobulin-like domains in prokaryotic cells |
| DE4228457A1 (de) | 1992-08-27 | 1994-04-28 | Beiersdorf Ag | Herstellung von heterodimerem PDGF-AB mit Hilfe eines bicistronischen Vektorsystems in Säugerzellen |
| AU6819494A (en) | 1993-04-26 | 1994-11-21 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| SG54115A1 (en) | 1993-04-27 | 1998-11-16 | Gerber Scient Products Inc | Thermal printing apparatus with improved power supply |
| AU691811B2 (en) | 1993-06-16 | 1998-05-28 | Celltech Therapeutics Limited | Antibodies |
| CA2163364C (en) | 1993-07-14 | 2009-10-27 | Francis C. Szoka, Jr. | Self-assembling polynucleotide delivery system comprising dendrimer polycations |
| US5534241A (en) | 1993-07-23 | 1996-07-09 | Torchilin; Vladimir P. | Amphipathic polychelating compounds and methods of use |
| US6087171A (en) | 1993-12-17 | 2000-07-11 | Spinal Cord Society | Method for inducing DNA synthesis in neurons |
| US5830686A (en) | 1994-01-13 | 1998-11-03 | Calydon | Tissue-specific enhancer active in prostate |
| US6057299A (en) | 1994-01-13 | 2000-05-02 | Calydon, Inc. | Tissue-specific enhancer active in prostate |
| US5651981A (en) | 1994-03-29 | 1997-07-29 | Northwestern University | Cationic phospholipids for transfection |
| WO1995031183A1 (en) * | 1994-05-16 | 1995-11-23 | Washington University | Cell membrane fusion composition and method |
| US6110666A (en) | 1994-06-09 | 2000-08-29 | Medical Research Council | Locus control subregions conferring integration-site independent transgene expression abstract of the disclosure |
| FR2722208B1 (fr) | 1994-07-05 | 1996-10-04 | Inst Nat Sante Rech Med | Nouveau site interne d'entree des ribosomes, vecteur le contenant et utilisation therapeutique |
| US5527928A (en) | 1994-09-30 | 1996-06-18 | Nantz; Michael H. | Cationic transport reagents |
| WO1996013250A1 (en) | 1994-10-27 | 1996-05-09 | Amgem Inc. | Compositions for increased bioavailability of orally delivered therapeutic agents |
| US5786214A (en) | 1994-12-15 | 1998-07-28 | Spinal Cord Society | pH-sensitive immunoliposomes and method of gene delivery to the mammalian central nervous system |
| US6008202A (en) | 1995-01-23 | 1999-12-28 | University Of Pittsburgh | Stable lipid-comprising drug delivery complexes and methods for their production |
| US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
| US6121022A (en) | 1995-04-14 | 2000-09-19 | Genentech, Inc. | Altered polypeptides with increased half-life |
| US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
| US5780052A (en) | 1995-04-24 | 1998-07-14 | Northeastern University | Compositions and methods useful for inhibiting cell death and for delivering an agent into a cell |
| US5834012A (en) | 1995-05-03 | 1998-11-10 | Roman Perez-Soler | Lipid complexed topoisomerase I inhibitors |
| JP3735921B2 (ja) | 1996-02-07 | 2006-01-18 | 三菱ウェルファーマ株式会社 | GPIb・脂質複合体およびその用途 |
| US6077834A (en) | 1996-02-09 | 2000-06-20 | Cheng; Pi-Wan | Receptor ligand-facilitated delivery of biologically active molecules |
| EP0914094A4 (en) | 1996-03-28 | 2000-03-01 | Univ Illinois | MATERIALS AND METHOD FOR PRODUCING IMPROVED LIPOSOMAL AGENTS |
| WO1997038010A2 (en) | 1996-04-11 | 1997-10-16 | The University Of British Columbia | Fusogenic liposomes |
| JP3919227B2 (ja) | 1996-05-02 | 2007-05-23 | テルモ株式会社 | アミジン誘導体及びそれを構成成分とする薬物担体 |
| US5928906A (en) | 1996-05-09 | 1999-07-27 | Sequenom, Inc. | Process for direct sequencing during template amplification |
| ATE252372T1 (de) | 1996-08-23 | 2003-11-15 | Sequus Pharm Inc | Liposome enthaltend cisplatin |
| US7384923B2 (en) | 1999-05-14 | 2008-06-10 | Lipoxen Technologies Limited | Liposomes |
| US6056973A (en) | 1996-10-11 | 2000-05-02 | Sequus Pharmaceuticals, Inc. | Therapeutic liposome composition and method of preparation |
| TW520297B (en) | 1996-10-11 | 2003-02-11 | Sequus Pharm Inc | Fusogenic liposome composition and method |
| US6153596A (en) | 1996-12-18 | 2000-11-28 | Emory University | Polycationic oligomers |
| EA002630B1 (ru) | 1997-02-05 | 2002-08-29 | Фармация Энд Апджон Компани | Способ получения липидных комплексов или липосом водонерастворимого диаминоциклогександикарбоксилата платины |
| US6277375B1 (en) | 1997-03-03 | 2001-08-21 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
| US6060082A (en) | 1997-04-18 | 2000-05-09 | Massachusetts Institute Of Technology | Polymerized liposomes targeted to M cells and useful for oral or mucosal drug delivery |
| US6524613B1 (en) | 1997-04-30 | 2003-02-25 | Regents Of The University Of Minnesota | Hepatocellular chimeraplasty |
| EP0983303B1 (en) | 1997-05-21 | 2006-03-08 | Biovation Limited | Method for the production of non-immunogenic proteins |
| JP3614866B2 (ja) | 1997-06-12 | 2005-01-26 | リサーチ コーポレイション テクノロジーズ,インコーポレイティド | 人工抗体ポリペプチド |
| DE69838584T2 (de) | 1997-08-04 | 2008-06-26 | Cell Genesys, Inc., Foster City | Enhancer des menschlichen glandulären kallikreingens, vektoren die ihn enthalten und methoden für seine verwendung |
| US6749863B1 (en) | 1997-11-19 | 2004-06-15 | Georgetown University | Targeted liposome gene delivery |
| ES2339421T3 (es) | 1997-11-19 | 2010-05-20 | Georgetown University | Administracion genica mediante liposoma dirigido. |
| AU1656799A (en) | 1997-12-12 | 1999-07-05 | Inex Pharmaceuticals Corp. | Cationic drugs encapsulated in anionic liposomes |
| US6320017B1 (en) | 1997-12-23 | 2001-11-20 | Inex Pharmaceuticals Corp. | Polyamide oligomers |
| US6573101B1 (en) | 1998-02-12 | 2003-06-03 | The Regents Of The University Of California | Compositions for receptor/liposome mediated transfection and methods of using same |
| US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
| JP4334141B2 (ja) | 1998-04-20 | 2009-09-30 | グリカート バイオテクノロジー アクチェンゲゼルシャフト | 抗体依存性細胞傷害性を改善するための抗体のグリコシル化操作 |
| US6245427B1 (en) | 1998-07-06 | 2001-06-12 | DüZGüNES NEJAT | Non-ligand polypeptide and liposome complexes as intracellular delivery vehicles |
| HUP0104865A3 (en) | 1999-01-15 | 2004-07-28 | Genentech Inc | Polypeptide variants with altered effector function |
| US7311924B2 (en) | 1999-04-01 | 2007-12-25 | Hana Biosciences, Inc. | Compositions and methods for treating cancer |
| US6723338B1 (en) | 1999-04-01 | 2004-04-20 | Inex Pharmaceuticals Corporation | Compositions and methods for treating lymphoma |
| EP2275540B1 (en) | 1999-04-09 | 2016-03-23 | Kyowa Hakko Kirin Co., Ltd. | Method for controlling the activity of immunologically functional molecule |
| DE19925143A1 (de) | 1999-06-02 | 2000-12-07 | Aventis Pharma Gmbh | Neue liposomale Vektorkomplexe und deren Verwendung für die Gentherapie |
| JP2001002592A (ja) | 1999-06-18 | 2001-01-09 | Dai Ichi Seiyaku Co Ltd | 遺伝子導入用組成物 |
| NZ517202A (en) | 1999-08-24 | 2004-05-28 | Medarex Inc | Human CTLA-4 antibodies and their uses |
| AU1776801A (en) | 1999-11-24 | 2001-06-04 | Liposome Company, Inc., The | Modular targeted liposomal delivery system |
| EP1242609A2 (en) | 1999-12-30 | 2002-09-25 | Novartis AG | Novel colloid synthetic vectors for gene therapy |
| CA2733819A1 (en) | 1999-12-30 | 2001-07-12 | Judith K. Gwathmey | Iron chelator delivery system |
| US6530944B2 (en) | 2000-02-08 | 2003-03-11 | Rice University | Optically-active nanoparticles for use in therapeutic and diagnostic methods |
| DE60130741T2 (de) | 2000-03-02 | 2008-07-03 | Mitsubishi Pharma Corp. | GPib-GEBUNDENES KONSTRUKT UND VERWENDUNGEN DAVON |
| DK1272160T3 (da) | 2000-04-12 | 2007-05-21 | Liplasome Pharma As | Lipidbaseret lægemiddelleveringssystem til topisk applikation |
| JP2004511426A (ja) | 2000-05-03 | 2004-04-15 | ミュンヘン バイオテク アーゲー | 活性化血管部位に関連する陽イオン性の診断薬、画像化剤、および治療薬 |
| US20030059461A1 (en) | 2000-06-06 | 2003-03-27 | Sibtech, Inc. | Molecular delivery vehicle for delivery of selected compounds to targets |
| US20030072794A1 (en) | 2000-06-09 | 2003-04-17 | Teni Boulikas | Encapsulation of plasmid DNA (lipogenes™) and therapeutic agents with nuclear localization signal/fusogenic peptide conjugates into targeted liposome complexes |
| US20040234588A1 (en) | 2000-09-21 | 2004-11-25 | University Of Georgia Research Foundation, Inc. | Artificial lipoprotein carrier system for bioactive materials |
| EP1209469A1 (en) | 2000-11-22 | 2002-05-29 | Vectron Therapeutics AG | Production and use of a targeted diagnostic system |
| DE60131456T2 (de) | 2000-11-30 | 2008-07-10 | Medarex, Inc., Milpitas | Transchromosomale transgen-nagetiere zur herstellung von humanen antikörpern |
| JP2004524516A (ja) | 2000-12-12 | 2004-08-12 | オーストラリアン インスティチュート オブ マリーン サイエンス | 麻痺性貝毒のアッセイ |
| US6897196B1 (en) | 2001-02-07 | 2005-05-24 | The Regents Of The University Of California | pH sensitive lipids based on ortho ester linkers, composition and method |
| FI113840B (fi) | 2001-03-26 | 2004-06-30 | Ctt Cancer Targeting Tech Oy | Matriisi-metalloproteinaasi-inhibiittorien käyttö liposomien kohdentamisessa |
| ES2464532T3 (es) | 2001-04-19 | 2014-06-03 | The Scripps Research Institute | Métodos y composiciones para la producción de pares ortogonales de ARNt-aminoacil-ARNt sintetasa |
| JP2004535388A (ja) | 2001-04-30 | 2004-11-25 | ターゲティッド ジェネティクス コーポレイション | 脂質含有薬物送達複合体およびそれらの生成方法 |
| WO2002089772A1 (en) | 2001-05-09 | 2002-11-14 | Inex Pharmaceuticals Corporation | Anti-angiogenic therapy using liposome-encapsulated chemotherapeutic agents |
| JP2004532038A (ja) | 2001-05-17 | 2004-10-21 | ディヴァーサ コーポレイション | 新規抗原結合分子の治療、診断、予防、酵素、産業ならびに農業各分野への応用とそのための新規抗原結合分子の作製とスクリーニングの方法 |
| US20040142325A1 (en) * | 2001-09-14 | 2004-07-22 | Liat Mintz | Methods and systems for annotating biomolecular sequences |
| AU2002330139A1 (en) | 2001-10-03 | 2003-04-14 | Vanderbilt University | In vivo panning for ligands to radiation-induced molecules |
| PL213948B1 (pl) | 2001-10-25 | 2013-05-31 | Genentech Inc | Kompozycje zawierajace glikoproteine, czasteczka kwasu nukleinowego kodujaca te glikoproteine, komórka gospodarza, sposób wytwarzania glikoproteiny, kompozycja do zastosowania do leczenia, zastosowanie kompozycji i zestaw zawierajacy kompozycje |
| WO2003044214A2 (en) | 2001-11-20 | 2003-05-30 | Baylor College Of Medicine | Methods and compositions in checkpoint signaling |
| US6476068B1 (en) | 2001-12-06 | 2002-11-05 | Pharmacia Italia, S.P.A. | Platinum derivative pharmaceutical formulations |
| US7939059B2 (en) | 2001-12-10 | 2011-05-10 | California Institute Of Technology | Method for the generation of antigen-specific lymphocytes |
| US20030220284A1 (en) | 2002-02-22 | 2003-11-27 | Patricia Yotnda | Delivery of adenoviral DNA in a liposomal formulation for treatment of disease |
| AU2003217912A1 (en) | 2002-03-01 | 2003-09-16 | Xencor | Antibody optimization |
| US20030228285A1 (en) | 2002-05-03 | 2003-12-11 | Mien-Chie Hung | Bipartite T-cell factor (Tcf)-responsive promoter |
| US20040022842A1 (en) | 2002-06-03 | 2004-02-05 | Mebiopharm Co., Ltd. | Liposome preparations containing oxaliplatin |
| JP3415131B1 (ja) | 2002-06-03 | 2003-06-09 | メビオファーム株式会社 | リポソーム製剤 |
| EP1519714B1 (en) | 2002-06-28 | 2010-10-20 | Protiva Biotherapeutics Inc. | Method and apparatus for producing liposomes |
| MXPA05003983A (es) | 2002-10-16 | 2005-06-22 | Scripps Research Inst | Incorporacion en sitio especifico de cetoaminoacidos en proteinas. |
| EP1558747B1 (en) | 2002-10-16 | 2009-10-14 | The Scripps Research Institute | Glycoprotein synthesis |
| EA008497B1 (ru) | 2002-11-21 | 2007-06-29 | Певион Биотех Лтд. | Высокоэффективные способные к слиянию везикулы, способ их получения и фармацевтическая композиция, их содержащая |
| JP5642916B2 (ja) | 2003-04-17 | 2014-12-17 | ザ スクリプス リサーチ インスティテュート | 真核遺伝コードの拡張 |
| EP1704242A4 (en) | 2003-07-07 | 2008-06-18 | Scripps Research Inst | COMPOSITIONS WITH PAIRS OF ORTHOGONAL LEUCYL-TRNA AND AMINOACYL-TRNA-SYNTHETASE AND USES THEREOF |
| WO2005007624A2 (en) | 2003-07-07 | 2005-01-27 | The Scripps Research Institute | Compositions of orthogonal glutamyl-trna and aminoacyl trna synthetase pairs and uses thereof |
| US7947493B2 (en) | 2003-07-09 | 2011-05-24 | Wisconsin Alumni Research Foundation | Compositions and methods for regulating mRNA transcription and translation |
| US7981843B2 (en) | 2004-01-20 | 2011-07-19 | Kalobios Pharmaceuticals, Inc. | Antibody specificity transfer using minimal essential binding determinants |
| MX2007003142A (es) | 2004-09-21 | 2007-07-04 | Scripps Research Inst | Incorporacion in vivo de alquinil aminoacidos a proteinas en eubacterias. |
| MX2007004892A (es) | 2004-10-27 | 2007-08-16 | Scripps Research Inst | Componentes de traduccion ortogonales para la incorporacion in vivo de aminoacidos no naturales. |
| JP2006248978A (ja) | 2005-03-10 | 2006-09-21 | Mebiopharm Co Ltd | 新規なリポソーム製剤 |
| JP5603012B2 (ja) | 2005-12-02 | 2014-10-08 | トヘ モウント シナイ スクール オフ メディシネ オフ ニューヨーク ウニベルシトイ | 非天然表面タンパク質を提示するキメラウイルス及びその使用 |
| MX2008011470A (es) | 2006-03-09 | 2008-09-24 | Scripps Research Inst | Sistemas para la expresion de componentes de traduccion ortogonales en celulas huesped eubacterianas. |
| GB0606954D0 (en) * | 2006-04-06 | 2006-05-17 | Randox Lab Ltd | Method |
| CN101583346B (zh) | 2006-04-28 | 2015-08-19 | 儿童医院医疗中心 | 用于穿膜药物递送系统的皂化蛋白c和相关蛋白及肽的促融合性质 |
| WO2008140621A2 (en) | 2006-12-21 | 2008-11-20 | Mount Sinai School Of Medicine Of New York University | Transgenic oncolytic viruses and uses thereof |
| EP2118150B1 (en) | 2007-02-14 | 2015-09-23 | Biocompatibles UK Limited | Derivatisation of biological molecules |
| CA2688804A1 (en) | 2008-12-17 | 2010-06-17 | The Uab Research Foundation | Polycistronic vector for human induced pluripotent stem cell production |
| EP2393921B1 (en) | 2009-02-05 | 2015-07-15 | Icahn School of Medicine at Mount Sinai | Chimeric newcastle disease viruses and uses thereof |
| FR2945538B1 (fr) | 2009-05-12 | 2014-12-26 | Sanofi Aventis | Anticorps humanises specifiques de la forme protofibrillaire du peptide beta-amyloide. |
| CA2813300A1 (en) | 2010-09-29 | 2012-04-05 | Innovascreen Inc. | Recombinant polypeptides for membrane fusion and uses thereof |
| JP6091435B2 (ja) | 2011-02-22 | 2017-03-08 | カリフォルニア インスティチュート オブ テクノロジー | アデノ随伴ウイルス(aav)ベクターを用いたタンパク質の送達 |
| WO2013078433A1 (en) | 2011-11-23 | 2013-05-30 | University Of Hawaii | Auto-processing domains for polypeptide expression |
| EP2807274B1 (en) * | 2012-01-27 | 2019-01-23 | Vib Vzw | Monocyte biomarkers for cancer detection |
| PE20151921A1 (es) | 2013-03-14 | 2015-12-26 | Icahn School Med Mount Sinai | Virus de la enfermedad de newcastle y usos de los mismos |
-
2017
- 2017-11-10 CN CN201780070035.4A patent/CN109996809A/zh active Pending
- 2017-11-10 EP EP17808174.1A patent/EP3538546B1/en active Active
- 2017-11-10 US US16/349,553 patent/US11339209B2/en active Active
- 2017-11-10 JP JP2019524896A patent/JP2020500020A/ja not_active Ceased
- 2017-11-10 WO PCT/IB2017/057060 patent/WO2018087720A1/en not_active Ceased
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014210448A1 (en) * | 2013-06-27 | 2014-12-31 | The Board Of Regents Of The University Of Texas System | Compositions and methods relating to myomaker-induced muscle cell fusion |
Non-Patent Citations (1)
| Title |
|---|
| DATABASE UNIPROT[ONLINE],ACCESSION NO. A0A1B0GTQ4, 05-10-2016 LAST MODIFIED, <HTTP:// HTTPS://WWW.UN, JPN6021052567, ISSN: 0004803592 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2020508668A (ja) * | 2017-02-24 | 2020-03-26 | ザ ボード オブ リージェンツ オブ ザ ユニバーシティー オブ テキサス システム | ミオミキサーにより促進される筋細胞融合に関連する組成物および方法 |
| JP7332474B2 (ja) | 2017-02-24 | 2023-08-23 | ザ ボード オブ リージェンツ オブ ザ ユニバーシティー オブ テキサス システム | ミオミキサーにより促進される筋細胞融合に関連する組成物および方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| US20190263899A1 (en) | 2019-08-29 |
| EP3538546B1 (en) | 2025-01-08 |
| EP3538546A1 (en) | 2019-09-18 |
| WO2018087720A1 (en) | 2018-05-17 |
| CN109996809A (zh) | 2019-07-09 |
| US11339209B2 (en) | 2022-05-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11339209B2 (en) | Compositions, methods, and therapeutic uses related to fusogenic protein minion | |
| JP2025072522A (ja) | 環状rna組成物及び方法 | |
| US20210284709A1 (en) | Hpv-specific binding molecules | |
| CN107667120B (zh) | 抗muc16抗体及其应用 | |
| US20170283807A1 (en) | Compositions and methods for diagnosis and treatment of prostate cancer | |
| BR112021008289A2 (pt) | Métodos para tratamento utilizando receptores de antígeno quimérico específico para antígeno de maturação de célula b | |
| BR122022000386B1 (pt) | Anticorpos que se ligam a cd39, composição farmacêutica e kit dos mesmos | |
| KR20190120233A (ko) | Rna 암 백신 | |
| CN113573729A (zh) | 前列腺新抗原及其用途 | |
| EP2010226B1 (en) | Transcobalamin receptor polypeptides, nucleic acids, and modulators thereof, and related methods of use in modulating cell growth and treating cancer and cobalamin deficiency | |
| JP2023508616A (ja) | 治療部位での免疫系応答性を刺激し維持するためのナノ粒子システム | |
| UA125817C2 (uk) | Пептид, придатний для лікування та/або діагностики раку | |
| US20230149460A1 (en) | Methods for generating engineered memory-like nk cells and compositions thereof | |
| KR20210102331A (ko) | 암 및 기타 질환의 진단 및 치료를 위한 종양 촉진 암종 관련 섬유아세포의 식별 및 표적화 | |
| CN116942851A (zh) | Wnt信号传递激动剂分子 | |
| CN114641310A (zh) | 治疗癌症和其他疾病的靶向α3β1整合素 | |
| JP2025517968A (ja) | 免疫応答を調節するための組成物及び方法 | |
| KR20240035798A (ko) | 방법 및 조성물 | |
| CN115485395A (zh) | 用于治疗癌症的包含剪接-衍生的抗原的组合物和方法 | |
| JP2025517967A (ja) | サイトカインを調節するための組成物及び方法 | |
| CN115485295A (zh) | NPM1c阳性癌症的免疫疗法的组合物和方法 | |
| CN119095614A (zh) | 治疗剂和诊断剂以及其用途 | |
| TW202241479A (zh) | 遞送外來抗原之溶瘤病毒及表現靶向外來抗原之嵌合受體之經工程化免疫細胞之組合療法 | |
| JP2023514566A (ja) | 卵巣癌におけるネオ抗原の発現及びその使用 | |
| US20250041341A1 (en) | Polypeptides targeting cd105+ cancers |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20201109 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20201109 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20220105 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20220314 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220603 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20220621 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220916 |
|
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20221004 |
|
| A045 | Written measure of dismissal of application [lapsed due to lack of payment] |
Free format text: JAPANESE INTERMEDIATE CODE: A045 Effective date: 20230228 |